Toll-like receptor 4 D299G polymorphism in metabolic disorders: a meta-analysis

被引：0
作者：
F. S. Belforte
F. Coluccio Leskow
E. Poskus
A. Penas Steinhardt
机构：
[1] Facultad de Farmacia y Bioquímica,Laboratorio de Biología Molecular: INIGEM CONICET
[2] Universidad de Buenos Aires,UBA & Cátedra de Genética y Bilogía Molecular
[3] Facultad de Ciencias Exactas y Naturales,Departamento de Química Biológica
[4] Universidad de Buenos Aires,División Endocrinología, “Hospital de Clínicas”
[5] IQUIBICEN-CONICET; & Departamento de Ciencias Básicas,undefined
[6] Universidad Nacional de Lujan,undefined
[7] Instituto de Estudios de la Inmunidad Humoral (IDEHU),undefined
[8] CONICET-UBA & Cátedra de Inmunología,undefined
[9] Facultad de Farmacia y Bioquímica,undefined
[10] Universidad de Buenos Aires,undefined
[11] Universidad de Buenos Aires (UBA),undefined
来源：
Molecular Biology Reports | 2013年 / 40卷
关键词：
TLR4; Meta-analysis; D299G; Polymorphism; Diabetes; Metabolic syndrome;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The toll-like receptor 4 (TLR4) plays a key role in the activation of innate immune response participating in the recognition of lipopolysaccharides. Changes in the innate immune response are involved in the pathogenesis of some metabolic disorders such as metabolic syndrome and type 2 diabetes mellitus (Met-S and T2DM). It has been recently shown the role of gut microbiota in the perpetuation of both insulin resistance and low-grade chronic inflammation. Some studies have reported that TLR4 D299G polymorphism is associated with metabolic disorders, however results have been inconsistent. Two recent meta-analyses showed that D299G is associated with inflammatory bowel disease and gastrointestinal cancers risk, two pathological states in which the luminal microbial flora-host cells interaction may be implicated. We conducted a systemic review of the published data considering all eligible published studies (six studies with 1696 cases and 3388 controls for D299G) and a meta-analysis was performed to evaluate the association between TLR4 D299G polymorphism and the risk for metabolic disorders. Five studies were identified for T2DM: three corresponding to Caucasian populations and two to mixed populations. The remaining study analyzed Met-S in a Caucasian population. We observed a significant association between D299G polymorphism and metabolic disorders (T2DM and Met-S) risk (OR = 0.566, 95 % CI: 0.347–0.925, p = 0.023) particularly in Caucasians. No association was found in mixed population subgroup. Our meta-analysis identified that the AG/GG genotypes of D299G are associated with decreased metabolic disorders risk.
引用
收藏
页码：3015 / 3020
页数：5
相关论文
共 58 条
  • [1] Rock FL(1998)A family of human receptors structurally related to Drosophila Toll Proc Natl Acad Sci USA 95 588-593
  • [2] Hardiman G(2003)Toll-like receptor signaling pathways Science 300 1524-1525
  • [3] Timans JC(1998)Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41 1241-1248
  • [4] Kastelein RA(2003)Toll-like receptors Ann Rev Immunol 21 335-1998
  • [5] Bazan JF(2006)Inflammation and metabolic disorders Nature 444 860-191
  • [6] Barton GM(2007)Loss-of-function mutation in toll-like receptor 4 prevents diet-induced obesity and insulin resistance Diabetes 56 1986-4515
  • [7] Medzhitov R(2000)TLR4 mutations are associated with endotoxin hyporesponsiveness in humans Nat Genet 25 187-560
  • [8] Pickup JC(2008)Functional consequences of toll-like receptor 4 polymorphisms Mol Med 14 346-4
  • [9] Crook MA(2012)The Asp299Gly polymorphism alters TLR4 signaling by interfering with recruitment of MyD88 and TRIF J Immunol 188 4506-16650
  • [10] Takeda K(2003)Measuring inconsistency in meta-analyses BMJ 327 557-15
123456